Consistent with this concept are studies demonstrating that high-level leukemia-cell expression of ROR1 can enhance disease progression in mouse models [9], and associate with a shorter median time from diagnosis to initial therapy and shorter survival for patients with CLL [10]. The gene discussed is ROR1; the disease is B-cell chronic lymphocytic leukemia.